MT3 and Alzheimer disease: One cautionary note is while our findings support the role of astrocytic Mt3 downregulation in accumulation of Aβ, the fact that Mt3 downregulation may reduce the potential boosting effect of cAMP on lysosomal functions, would diminish the potential relevance of cilostazol or other PDE inhibitors as a therapeutic measure in AD.